Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen
CA 2272407 C · Owner: Vijayasaradhi, Setaluri · Inventors: Naftzger, Clarissa; Houghton, Alan; Vijayasaradhi, Setaluri
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Tolerance of the immune system for self-differentiation antigens can be overcome and an immune response stimulated by administration of a therapeutic differentiation antigen. The therapeutic differentiation antigen is altered with respect to the target differentiation antigen in the individual being treated (i.e. the differentiation antigen to which an immune response is desired) in one of three ways. First, the therapeutic differentiation antigen may be syngeneic with the target differentiation antigen provided that , therapeutic differentiation antigen is expressed in cells of a species different from the individual being treated. For example a human , differentiation antigen …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 10, 1997 and granted July 31, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 10, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 10, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.